Référentiel des médicaments
Dostarlimab
Dostarlimab is a medicine in the class oncology. It is used for cancer.
- Classe médicamenteuse: Oncology
- Indications: cancer
Dernière mise à jour Sources: US FDA label
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Oncology
- Code ATC
- L01FF07
- Formes courantes
- injection
- Dosages courants
- 50 mg/ml
- Interactions connues
- 3 (Modérée: 2 · Mineure: 1)
- Noms commerciaux
- 2
- Pays et marchés
- 2
Indications
Mécanisme d'action
Dostarlimab-gxly is a humanized IgG4 monoclonal antibody that binds the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
Posologie adulte habituelle (résumé de la notice)
Primary advanced or recurrent endometrial cancer: 500 mg IV every 3 weeks for 6 cycles with carboplatin and paclitaxel, then 1,000 mg monotherapy every 6 weeks thereafter; until disease progression, unacceptable toxicity, or up to 3 years
Grossesse et allaitement
- Grossesse
- Unsafe Can cause fetal harm: PD-1 blockade can disrupt immune tolerance to the fetus and raise the risk of pregnancy loss; IgG4 crosses the placenta. Check pregnancy status; use effective contraception during treatment and for 4 months after the last dose.
- Allaitement
- Unsafe No data on milk levels. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 4 months after the last dose.
Effets indésirables signalés
- Fatigue/asthenia
- Anemia
- Diarrhea
- Nausea
- Peripheral neuropathy (with carboplatin/paclitaxel)
- Alopecia (with carboplatin/paclitaxel)
Précautions particulières
- Severe and fatal immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, transplant rejection) can occur in any organ; monitor liver enzymes, creatinine and thyroid function at baseline and periodically.
- Infusion-related reactions: interrupt, slow the infusion, or permanently discontinue based on severity.
- Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after PD-1/PD-L1 blocking antibody.
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (3)
- Dostarlimab + Piperacillin Moderate
- Dostarlimab + Piperacillin-tazobactam Moderate
- Dostarlimab + Penicillin g Minor
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Dostarlimab : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- IV preparation and dilution
Essayez Pro+ gratuitement pendant 7 jours sur le web. Sans carte.
Autres médicaments de cette classe
Questions fréquentes
What is Dostarlimab used for?
Dostarlimab is a medicine in the class oncology. It is used for Cancer, Endometrial carcinoma.
What side effects have been reported with Dostarlimab?
Fatigue/asthenia, Anemia, Diarrhea, Nausea, Peripheral neuropathy (with carboplatin/paclitaxel), Alopecia (with carboplatin/paclitaxel).
Can Dostarlimab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: PD-1 blockade can disrupt immune tolerance to the fetus and raise the risk of pregnancy loss; IgG4 crosses the placenta. Check pregnancy status; use effective contraception during treatment and for 4 months after the last dose. Breastfeeding: Unsafe. No data on milk levels. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 4 months after the last dose.
What does Dostarlimab interact with?
MediHelp lists 3 known interactions for Dostarlimab. Moderate: 2 · Minor: 1. The most serious include Piperacillin, Piperacillin-tazobactam, Penicillin g.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
